TransMedics Group, Inc. (TMDX) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $65.71 (-2.10%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Oct 30, 2025 | Matt O'Brien | Piper Sandler | $140.00 | +113.1% |
| Oct 30, 2025 | Jason Mills | Canaccord Genuity | $147.00 | +123.7% |
| Dec 11, 2024 | David Rescott | Robert W. Baird | $120.00 | +82.6% |
| Dec 11, 2024 | Matt O'Brien | Piper Sandler | $90.00 | +37.0% |
| Oct 29, 2024 | Joe Vruwink | Robert W. Baird | $150.00 | +128.3% |
| Oct 29, 2024 | Jason Mills | Canaccord Genuity | $109.00 | +65.9% |
| Oct 29, 2024 | Mike Matson | Needham | $109.00 | +65.9% |
| Oct 29, 2024 | Suraj Kalia | Oppenheimer | $125.00 | +90.2% |
| Sep 23, 2024 | David Rescott | Robert W. Baird | $200.00 | +204.4% |
| Sep 4, 2024 | Matt O'Brien | Piper Sandler | $180.00 | +173.9% |
| Aug 21, 2024 | Mike Matson | Needham | $208.00 | +216.5% |
| Aug 1, 2024 | William Plovanic | Canaccord Genuity | $169.00 | +157.2% |
| Aug 1, 2024 | Suraj Kalia | Oppenheimer | $200.00 | +204.4% |
| Jul 15, 2024 | Patrick Wood | Morgan Stanley | $145.00 | +120.7% |
| Jul 15, 2024 | Matt O'Brien | Piper Sandler | $170.00 | +158.7% |
| Jun 3, 2024 | George Sellers | Stephens | $151.00 | +129.8% |
Top Analysts Covering TMDX
TMDX vs Sector & Market
| Metric | TMDX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.27 | 2.25 | 2.41 |
| Analyst Count | 15 | 8 | 19 |
| Target Upside | +51.6% | +153002.0% | +21.5% |
| P/E Ratio | 15.04 | 3.46 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $195M | $198M | $201M | 5 |
| 2027-03-31 | $205M | $209M | $212M | 3 |
| 2027-06-30 | $221M | $225M | $228M | 3 |
| 2027-09-30 | $204M | $208M | $211M | 3 |
| 2027-12-31 | $227M | $231M | $234M | 3 |
| 2028-12-31 | $1.01B | $1.03B | $1.04B | 4 |
| 2029-12-31 | $1.20B | $1.21B | $1.23B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.61 | $0.63 | $0.64 | 4 |
| 2027-03-31 | $0.86 | $0.88 | $0.89 | 2 |
| 2027-06-30 | $0.94 | $0.96 | $0.98 | 2 |
| 2027-09-30 | $0.83 | $0.85 | $0.86 | 2 |
| 2027-12-31 | $0.90 | $0.92 | $0.94 | 2 |
| 2028-12-31 | $4.57 | $4.87 | $5.54 | 4 |
| 2029-12-31 | $5.74 | $5.81 | $5.91 | 2 |
Frequently Asked Questions
What is the analyst consensus for TMDX?
The consensus among 15 analysts covering TransMedics Group, Inc. (TMDX) is Buy with an average price target of $96.86.
What is the highest price target for TMDX?
The highest price target for TMDX is $208.00, set by Mike Matson at Needham on 2024-08-21.
What is the lowest price target for TMDX?
The lowest price target for TMDX is $90.00, set by Matt O'Brien at Piper Sandler on 2024-12-11.
How many analysts cover TMDX?
15 analysts have issued ratings for TransMedics Group, Inc. in the past 12 months.
Is TMDX a buy or sell right now?
Based on 15 analyst ratings, TMDX has a consensus rating of Buy (2.27/5) with a +51.6% upside to the consensus target of $96.86.
What are the earnings estimates for TMDX?
Analysts estimate TMDX will report EPS of $0.63 for the period ending 2026-12-31, with revenue estimated at $198M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.